OIMU
ALNY icon

Osmosis Investment Management UK’s Alnylam Pharmaceuticals ALNY Stock Holding History

Osmosis Investment Management UK’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Sell
7,013
-694
-9% -$236K 0.06% 228
2025
Q4 		$3.06M Buy
+7,707
New +$3.41M 0.08% 219

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osmosis Investment Management UK's ALNY Position: Q1 2026 in Review

Osmosis Investment Management UK reduced its Alnylam Pharmaceuticals (ALNY) stake by 9% in Q1 2026, selling an estimated $236K and leaving 7,013 shares worth $2.32M. The position accounts for 0.06% of the portfolio, ranked #228.

Osmosis Investment Management UK first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.06M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Osmosis Investment Management UK held 7,013 shares of Alnylam Pharmaceuticals worth $2.32M as of Q1 2026.
  • Osmosis Investment Management UK sold 694 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $236K.
  • Alnylam Pharmaceuticals made up 0.06% of Osmosis Investment Management UK's portfolio in Q1 2026, its #228 holding.
  • Osmosis Investment Management UK first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Osmosis Investment Management UK's Alnylam Pharmaceuticals position peaked at $3.06M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Osmosis Investment Management UK's 13F filing for Q1 2026, filed 14 May 2026.